Loading cancer entity…
Loading cancer entity…
Variants & evidence
10 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| NRG1 Fusion2 | ||||||||
| Afatinib | Mucinous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7490A 62 year old nonsmoker with KRAS and ERBB family wild-type metastatic pulmonary adenocarcinoma was found to have a CD74-NRG1 fusion. The patient achieved a durable response when treated with afatinib… (full text at CIViC) PMID 28502724 · Gay et al., 2017 · Open in CIViC | civic |
| 〃 | Mucinous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | submitted | EID7494A single case of pulmonary mucinous adenocarcinoma in a 62 year old patient was found to have a CD74-NRG1 fusion. Afatinib treatment resulted in symptomatic and radiographic response for 26 weeks, at … (full text at CIViC) PMID 29169524 · Cheema et al., 2017 · Open in CIViC | civic |
| ERBB2 Amplification1 | ||||||||
| Carboplatin + TrastuzumabCombination | Ovarian Mucinous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID13137Ovarian mucinous carcinoma responds poorly to paclitaxel and carboplatin, prompting interest in targeted therapy, and it resembles gastro-oesophageal adenocarcinoma, a tumour type in which HER2 (ERBB2… (full text at CIViC) PMID 20003286 · McAlpine et al., 2009 · Open in CIViC | civic |
| GNAS Mutation1 | ||||||||
| Palbociclib | Pseudomyxoma Peritonei | Predictive | B | Supports Sensitivity Response | 3 | accepted | EID13146This paper details a prospective single-arm personalized cancer therapy study with n = 16 patients. The disease type was peritoneal mucinous carcinomatosis, predominantly of appendiceal origin. Palboc… (full text at CIViC) PMID 39413348 · Weitz et al., 2025 · Open in CIViC | civic |
| GNAS R2011 | ||||||||
| (prognostic) | Pseudomyxoma Peritonei | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1994Significantly shorter median progression-free survival was observed in relapsed pseudomyxoma peritonei patients with GNAS mutations (N=9; 5.3 months) as compared to wild-type (N=6; not reached; p < 0.… (full text at CIViC) PMID 27154293 · Pietrantonio et al., 2016 · Open in CIViC | civic |
| KRAS Mutation1 | ||||||||
| (prognostic) | Pseudomyxoma Peritonei | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID159640 patients with pseudomyxoma peritonei underwent panel sequencing after cytoreductive surgery and hypertermic intraperitoneal chemotherapy (HIPEC). KRAS mutations were found in 72% of samples and KRA… (full text at CIViC) PMID 27502722 · Pietrantonio et al., 2016 · Open in CIViC | civic |
| KRAS Q22*1 | ||||||||
| Panitumumab | Colon Mucinous Adenocarcinoma | Predictive | C | Supports Resistance | 2 | accepted | EID1131A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relap… (full text at CIViC) PMID 19661358 · Palmirotta et al., 2009 · Open in CIViC | civic |
| NRG1 Fusion2 | ||||||||
| Afatinib | Mucinous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 3 | rejected | EID7489A 42 year old nonsmoker with metastatic lung adenocarcinoma that was wild-type for EGFR, KRAS, ROS1, and ALK, was found to have re-arranged NRG1. Treatment with afatanib resulted in rapid symptomatic … (full text at CIViC) PMID 28502724 · Gay et al., 2017 · Open in CIViC | civic |
| Erlotinib + LumretuzumabCombination | Mucinous Adenocarcinoma | Predictive | C | Supports Sensitivity Response | 2 | submitted | EID7495Two patients with EGFR/KRAS/ALK wild-type invasive mucinous adenocarcinoma of the lung were found to have SLC3A2-NRG1 fusions. Both patients were treated with combination lumretuzumab, an anti-HER3 mo… (full text at CIViC) PMID 30268483 · Kim et al., 2018 · Open in CIViC | civic |
| TP53 R213*1 | ||||||||
| (predisposing) | Salivary Gland Mucinous Adenocarcinoma | Predisposing | E | Supports Pathogenic | 3 | submitted | EID7321As seen in Figure 1, the R213* mutation is predominantly found in colorectal and breast cancers. The variant was described as being a frequent p53 nonsense mutation in melanoma, kidney chromophobe, es… (full text at CIViC) PMID 28249646 · Panaccione et al., 2017 · Open in CIViC | civic |
Data updated 22 hours agoSource updated unknownsource: civic (CC0)
Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.